Market Overview

Mallinckrodt Begins Trading on NYSE

Related MNK
Mallinckrodt Study Shows Acthar Primary Endpoint Not Met in Patients with Persistently Active Systemic Lupus Erythematosus
UPDATE: Mallinckrodt Pharmaceuticals to Acquire Therakos from Gores Group for $1.325B

Mallinckrodt plc (NYSE: MNK) begins “regular-way” trading today on the
New York Stock Exchange as an independent, global specialty
pharmaceuticals company under the symbol MNK. Mallinckrodt completed its
previously announced separation from Covidien plc (NYSE: COV) in a
spin-off to shareholders on Friday, June 28.

“Today marks a significant new chapter in Mallinckrodt's proud history,”
said Mark Trudeau, President and CEO of Mallinckrodt. “We are well
positioned to leverage the skills and capabilities that have been
developed over 145 years of pharmaceuticals industry experience. There
are many benefits to our being independent that will accrue to
Mallinckrodt's shareholders, customers and employees going forward. We
are excited about the growth opportunities that lie ahead.”

See full press release

Posted-In: News Guidance Contracts Asset Sales Management Global


Related Articles (COV + MNK)

View Comments and Join the Discussion!

Partner Center